Alectinib(Alecensa)

Alectinib was approved by the FDA in December 2015. It targets anaplastic lymphoma kinase (ALK) and the RET proto-oncogene. This drug is a prescription medication; please strictly follow your doctor’s instructions for its specific usage and dosage.

Target of Action

Anaplastic lymphoma kinase (ALK); RET proto-oncogene.

Dosage and Administration

Route and frequency of administration for Alectinib: Oral, twice daily.

The dosage of Alectinib should be adjusted according to the patient's actual condition; specific adjustments require consultation with a physician and strict adherence to medical advice.

Recommended reading: Dosage and Administration of Alectinib

Side Effects

Common side effects: Constipation, fatigue, rash, etc.

Serious side effects: Hepatotoxicity, pulmonary problems, bradycardia, etc.

Reference article: Side Effects of Alectinib

Use in Special Populations

Pregnancy: During treatment with Alectinib and for 5 weeks after the last dose, you should use effective contraception.

Breastfeeding: If you are breastfeeding or planning to breastfeed, it is unknown whether Alectinib passes into breast milk. Do not breastfeed during treatment with Alectinib and for 1 week after the last dose.

Daily Precautions

1. Emphasize the importance of taking Alectinib strictly as prescribed. Do not change the dose or interrupt treatment without your physician's approval. Inform patients that Alectinib capsules should be swallowed whole with food and must not be crushed, dissolved, or opened.

2. If a dose is missed or vomiting occurs after taking the medication, inform patients to take the next dose at the scheduled time; do not make up for the missed dose or take an extra dose due to vomiting.

3. Hepatotoxicity risk: Emphasize the importance of regular monitoring of liver function. If any signs or symptoms suggestive of hepatotoxicity (e.g., fatigue, loss of appetite, nausea, vomiting, right upper abdominal pain, jaundice, dark urine, generalized itching, unusual bleeding or bruising) occur, immediately inform your physician.

from FDA,2024.04